Evidence map›Paper›PMID 30388846›Full record

ArticleMolecules (Basel, Switzerland)2018

Imidazo[1,2-

Gábor J Szebeni, József A Balog, András Demjén, Róbert Alföldi, Vanessza L Végi, Liliána Z Fehér, Imola Mán, Edit Kotogány, Barbara Gubán, Péter Batár and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Imidazo[1,2-International journal of molecular sciences · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Gábor J SzebeniLaboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, H-6726 Szeged, Hungary. g.szebeni@avidinbiotech.com.ORCID 0000-0002-6998-5632
József A BalogLaboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, H-6726 Szeged, Hungary. jozsef.a.balog@gmail.com.
András DemjénAvidin Ltd., Alsó kikötő sor 11/D, H-6726 Szeged, Hungary. a.demjen@avidinbiotech.com.
Róbert AlföldiAvidin Ltd., Alsó kikötő sor 11/D, H-6726 Szeged, Hungary. r.alfoldi@avidinbiotech.com.
Vanessza L VégiLaboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, H-6726 Szeged, Hungary. vegi.vanessza@gmai.com.
Liliána Z FehérAvidin Ltd., Alsó kikötő sor 11/D, H-6726 Szeged, Hungary. l.feher@avidinbiotech.com.
Imola MánAvidin Ltd., Alsó kikötő sor 11/D, H-6726 Szeged, Hungary. i.noktaman@avidinbiotech.com.
Edit KotogányLaboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, H-6726 Szeged, Hungary. kotogany.edit@brc.mta.hu.
Barbara GubánDepartment of Dermatology and Allergology, University of Szeged, Korányi fasor 6, H-6720 Szeged, Hungary. gubanbarbi@gmail.com.
Péter BatárDepartment of Hematology, Institute of Internal Medicine, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary. pbatar@med.unideb.hu.
László HacklerAvidin Ltd., Alsó kikötő sor 11/D, H-6726 Szeged, Hungary. hackler@avidinbiotech.com.
Iván KanizsaiAvidin Ltd., Alsó kikötő sor 11/D, H-6726 Szeged, Hungary. i.kanizsai@avidinbiotech.com.ORCID 0000-0003-0109-7097
László G PuskásLaboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, H-6726 Szeged, Hungary. laszlo@avidinbiotech.com.
HUN-REN Szegedi Biológiai Kutatóközpont · HUUniversity of Szeged · HUUniversity of Debrecen · HU

Funding

National Research, Development and Innovation Office (NKFI), Hungary GINOP-2.3.2-15-2016-00030 and GINOP-2.3.2-15-2016-00001SUPPORTED BY THE UNKP-18-4 NEW NATIONAL EXCELLENCE PROGRAM OF THE MINISTRY OF HUMAN CAPACITIES UNKP-18-4-SZTE-73
6 · The paper itself

Abstract

Leukemia, the malignancy of the hematopoietic system accounts for 10% of cancer cases with poor overall survival rate in adults; therefore, there is a high unmet medical need for the development of novel therapeutics. Eight imidazo[1,2-

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell SurvivalDose-Response Relationship, DrugEvolution, MolecularHL-60 CellsHumansOxidative StressPyrazolesAntineoplastic AgentsPyrazolesacute myeloid leukemiaapoptosisimidazolepyrazoletoxicogenomics

Identifiers

PMID30388846
PMCPMC6278434
OpenAlexW2899349558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.